The global Isoniazid market is projected to witness steady expansion through 2031, driven primarily by the rising global burden of tuberculosis (TB) and increased government initiatives focused on infectious disease control. According to The Insight Partners, the market is expected to register a CAGR of 6.1% from 2025 to 2031, reflecting the drug’s continued importance in first-line TB...